Front Matter
Preliminary Material
Introduction
Table 1-1: Cholesterol Concentrations
Table 1-2: Epidemiologic Data for Dyslipidemia
Figure 1-1: Approach to Management of Dyslipidemia
Table 1-3: Comparison of ATP-III Guidelines, ACC/AHA 2013 Guidelines, and NLA Recommendations
Pathophysiology
Clinical Presentation, Diagnosis, and Disease Classification
Table 1-4: Major Risk Factors for ASCVD
Table 1-5: Criteria for Classification of ASCVD
Table 1-6: National Lipid Association Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels to Consider Drug Therapy
General Treatment Principles
Table 1-7: Components of Dietary Recommendations
American College of Cardiology/American Heart Association Guidelines
Table 1-8. Statin intensity
National Lipid Association Recommendations
Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement
Table 1-10. Drugs that Can Lead to or Worsen Dyslipidemias
Pharmacotherapy
Statins
Cholesterol Absorption Inhibitors
Bile Acid Sequestrants
Fibric Acid Derivatives
Nicotinic Acid
Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies
Monitoring
Table 1-12: Lipid Effects of Nonstatin Agents
Table 1-13: Clinical Conditions that Can Worsen Lipid Profiles
Clinical Questions and Controversies
What Impact Do Statins Have on Cognitive Function?
Do Statins Cause or Worsen Type 2 Diabetes?
Are Statins Safe to Use in Patients with Chronic Liver Disease?
What Drug-Drug Interactions Impact Statin Therapy?
Can Fibrates Be Safely Added to a Statin for the Management of Hypertriglyceridemia?
What Is the Best Way to Manage Suspected Statin-Induced Myalgia?
Should Co-enzyme Q10 Be Recommended for the Treatment and/or Prevention of Statin-Associated Muscle Aches?
Which Risk Calculator Is Best?
What Is the Best Strategy to Manage Residual Cardiovascular Risk?
What LDL-C Level Is Too Low?
Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?
What Is the Role of CRP in Determining CHD Risk and LDL-C Goals?
Back Matter
Future Treatments
References
DOI:
https://doi.org/10.37573/9781585284719.020
Restricted access